Sharon Shacham's most recent trade in Acrivon Therapeutics Inc was a trade of 20,275 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Acrivon Therapeutics Inc | Sharon Shacham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2025 | 20,275 | 20,275 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Sharon Shacham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 20,275 | 20,275 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Sharon Shacham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 35,235 | 35,235 | - | - | Stock Option (Right to Buy) | |
| Karyopharm Therapeutics Inc | Sharon Shacham | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2022 | 90,000 | 90,000 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Sharon Shacham | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2022 | 60,000 | 958,131 (1%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Sharon Shacham | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 27,000 | 27,000 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Sharon Shacham | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 21,000 | 719,983 (1%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Sharon Shacham | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 10.24 per share. | 28 Feb 2022 | 6,226 | 713,757 (1%) | 0% | 10.2 | 63,739 | Common Stock |
| Karyopharm Therapeutics Inc | Sharon Shacham | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 10.24 per share. | 28 Feb 2022 | 6,226 | 898,131 (1%) | 0% | 10.2 | 63,739 | Common Stock |
| Karyopharm Therapeutics Inc | Sharon Shacham | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.12 per share. | 17 Feb 2022 | 9,088 | 904,357 (1%) | 0% | 12.1 | 110,177 | Common Stock |
| Karyopharm Therapeutics Inc | Sharon Shacham | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.12 per share. | 17 Feb 2022 | 9,079 | 698,983 (1%) | 0% | 12.1 | 110,068 | Common Stock |
| Karyopharm Therapeutics Inc | Sharon Shacham | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 9.86 per share. | 07 Feb 2022 | 6,764 | 708,062 (1%) | 0% | 9.9 | 66,707 | Common Stock |
| Karyopharm Therapeutics Inc | Sharon Shacham | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 9.86 per share. | 07 Feb 2022 | 6,707 | 913,445 (1%) | 0% | 9.9 | 66,144 | Common Stock |
| Karyopharm Therapeutics Inc | Sharon Shacham | President & CSO | Sale of securities on an exchange or to another person at price $ 12.39 per share. | 18 Mar 2021 | 4,000 | 714,826 (1%) | 0% | 12.4 | 49,553 | Common Stock |